Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company has three platforms: its Oncology Innovation Platform, dedicated to the research and development of its proprietary drugs; its Commercial Platform, focused on the sales and marketing of its specialty drugs and the market development of its proprietary drugs; and its Global Supply Chain Platform, dedicated to providing a supply of active pharmaceutical ingredients for its clinical and commercial efforts. The company's clinical pipeline includes: Orascovery, Src Kinase inhibition, T-cell Receptor-engineered T-cells, and arginine deprivation therapy.

Barnwell Industries is engaged in the business of: acquiring, developing, producing and selling oil and natural gas in Canada including evaluating proposals by third parties with regard to participation in exploratory and developmental operations elsewhere; investing in land interests in Hawaii; and drilling water and water monitoring wells of varying depths in Hawaii, installing and repairing water pumping systems through its wholly-owned subsidiary, Water Resources International, Inc., which is the distributor for Floway pumps and equipment in the state of Hawaii.

Brainstorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; and Parkinson's disease. NurOwn? technology is based on manufacturing protocol, which induces the differentiation of purified and expanded bone marrow-derived mesenchymal stem cells and consistently generates cells that release multiple neurotrophic factors to modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.

Enterprise Products Partners is a provider of midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals and refined products. The company's midstream energy operations include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage, and export and import terminals; crude oil gathering, transportation, storage, and export and import terminals; petrochemical and refined products transportation, storage, export and import terminals, and related services; and a marine transportation business that operates primarily on the U.S. inland and Intracoastal Waterway systems.

FleetCor Technologies is provider of commercial payment solutions. The company's five primary product lines are Fuel, which provides fuel payment solutions to businesses and government entities who operate vehicle fleets, as well as to main oil companies;Lodging, which provides lodging payment solutions to employees who travel overnight for work purposes; Tolls, which provides an electronic toll and parking payments product; Corporate Payments, which include virtual cards, purchasing cards, travel and entertainment cards; and Gift, which provides gift card product management and processing services. Additionally, the company provides other payment products including fleet maintenance and employee benefits.

Globalstar provides mobile satellite services including voice and data communications services via satellite. The company provides the following communications services via satellite: two-way voice communication and data transmissions using mobile or fixed devices including its GSP-1700 phone; one-way or two-way communication and data transmissions using mobile devices, including its SPOT family of products such as SPOT X?, SPOT Gen3 and Trace; and one-way data transmissions using a mobile or fixed device that transmits its location and other information to a central monitoring station, including its commercial Simplex products, such as its battery and solar-powered SmartOne, STX-3 and STINGR.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. The company is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and other hematologic cancers. The company is also developing an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4.

Gran Tierra Energy, together with its subsidiaries, is a company focused on oil and gas exploration and production in Colombia. Co. is primarily engaged in the exploration and production of oil and natural gas. Co. has one reportable segment based on geographic organization, Colombia. As of Dec 31 2017, Co. had total estimated proved reserves of 59.3 million barrels of oil and natural gas equivalent, consisting of 58.9 million barrels of oil and 2.1 million cubic feet of natural gas.

HG Holdings has an interest in HC Government Realty Trust, Inc., which owns and operates a portfolio of single-tenant properties leased throughout the United States for occupancy by federal agencies including the Federal Bureau of Investigation, the Drug Enforcement Administration, the Social Security Administration and the Department of Transportation.

Pope Resources is engaged primarily in managing timber resources on its own properties as well as those owned by others. The company operates in four business segments: Partnership Timber, and Funds Timber, which both consist of growing, managing, harvesting, and marketing timber; Timberland Investment Management, which is engaged in organizing and managing private equity timber funds using capital invested by third parties and the company; and Real Estate, which is focused on a portfolio in the west Puget Sound region of Washington, most of which are legacy timberlands that have become suitable as development property owing to the expansion of the Puget Sound metropolitan and suburban areas.

Provention Bio is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. The company's principal product candidates include: PRV-031 (teplizumab, anti-CD3 mAb) for the interception of type 1 diabetes; PRV-015 (anti-IL-15 mAb) for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 (oral CSF-1R inhibitor) for the treatment of Crohn's disease; PRV-300 (anti-TLR3 mAb) for the treatment of ulcerative colitis; and PRV-3279 (humanized anti-CD32B and CD79B bispecific) for the treatment of lupus.

Replimune Group is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. The company's primary product candidate, RP1, is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4, a protein that inhibits the immune response to tumors. The company has designed its RP3 product candidate to express immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).

Syros Pharmaceuticals is a biopharmaceutical company engaged in the non-coding regulatory region of the genome to develop a new wave of medicines that control the expression of genes. The company's primary product candidates are: SY-1425, a selective retinoic acid receptor alpha agonist that is used to treat acute myeloid leukemia patients; SY-1365, a selective inhibitor of cyclin-dependent kinase 7 (CDK7), that is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors; and SY-5609, a CDK7 inhibitor that can be administered orally, which is being evaluated in investigational new drug application, enabling preclinical studies.